Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep:43:100915.
doi: 10.1016/j.nmni.2021.100915. Epub 2021 Jul 7.

Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients

F A Cadegiani  1   2 , A Goren  2 , C G Wambier  3 , J McCoy  2
Affiliations

Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients

F A Cadegiani et al. New Microbes New Infect. 2021 Sep.

Abstract

In a prospective observational study (pre-AndroCoV Trial), the use of nitazoxanide, ivermectin and hydroxychloroquine demonstrated unexpected improvements in COVID-19 outcomes when compared to untreated patients. The apparent yet likely positive results raised ethical concerns on the employment of further full placebo controlled studies in early-stage COVID-19. The present analysis aimed to elucidate, through a comparative analysis with two control groups, whether full placebo-control randomized clinical trials (RCTs) on early-stage COVID-19 are still ethically acceptable. The Active group (AG) consisted of patients enrolled in the Pre-AndroCoV-Trial (n = 585). Control Group 1 (CG1) consisted of a retrospectively obtained group of untreated patients of the same population (n = 137), and Control Group 2 (CG2) resulted from a precise prediction of clinical outcomes based on a thorough and structured review of indexed articles and official statements. Patients were matched for sex, age, comorbidities and disease severity at baseline. Compared to CG1 and CG2, AG showed reduction of 31.5-36.5% in viral shedding (p < 0.0001), 70-85% in disease duration (p < 0.0001), and 100% in respiratory complications, hospitalization, mechanical ventilation, deaths and post-COVID manifestations (p < 0.0001 for all). For every 1000 confirmed cases for COVID-19, at least 70 hospitalizations, 50 mechanical ventilations and five deaths were prevented. Benefits from the combination of early COVID-19 detection and early pharmacological approaches were consistent and overwhelming when compared to untreated groups, which, together with the well-established safety profile of the drug combinations tested in the Pre-AndroCoV Trial, precluded our study from continuing employing full placebo in early COVID-19.

Keywords: Antiandrogen; COVID-19; SARS-CoV-2; clinical equipoise; dutasteride; hydroxychloroquine; ivermectin; nitazoxanide; proxalutamide; spironolactone.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Rationale for the ethical questioning on the employment of placebo-control design in RCTs for early COVID-19.
Fig. 2
Fig. 2
Ethics in the employment of full placebo-control RCTs in early COVID-19.
See this image and copyright information in PMC

References

    1. Zhou F., Yu T., Du R. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;S0140–6736(20):30566–30573. [published online ahead of print, 2020 Mar 11] [published correction appears in Lancet. 2020 Mar 12;:] - PMC - PubMed
    1. Booth A., Reed A.B., Ponzo S., Yassaee A., Aral M., Plans D., Labrique A., Mohan D. Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis. PLoS One. 2021 Mar 4;16(3) doi: 10.1371/journal.pone.0247461. PMID: 33661992; PMCID: PMC7932512. - DOI - PMC - PubMed
    1. Cadegiani F.A. Repurposing existing drugs for COVID-19: an endocrinology perspective. BMC Endocr Disord. 2020 Sep 29;20(1):149. doi: 10.1186/s12902-020-00626-0. - DOI - PMC - PubMed
    1. Gustavo Wambier C., Mehta N., Goren A., Cadegiani F. COVID-19, androgens, and androgenic alopecia. Dermatol Rev. 2021;2:146–153. doi: 10.1002/der2.50. - DOI
    2. McCoy J., Wambier C.G., Herrera S., Vaño-Galván S., Gioia F., Comeche B., Ron R., Serrano-Villar S., Iwasiow R.M., Tayeb M.A., Cadegiani F.A., Mesinkovska N.A., Shapiro J., Sinclair R., Goren A. Androgen receptor genetic variant predicts COVID-19 disease severity: a prospective longitudinal study of hospitalized COVID-19 male patients. J Eur Acad Dermatol Venereol. 2021 Jan;35(1):e15–e17. doi: 10.1111/jdv.16956. Epub 2020 Oct 21. PMID: 32977355; PMCID: PMC7536899. - DOI - PMC - PubMed
    1. Cadegiani F., Lin E.M., Goren A., Wambier C.G. Potential risk for developing severe COVID-19 disease among anabolic steroid users. BMJ Case Rep. 2021 Feb 26;14(2) doi: 10.1136/bcr-2021-241572. PMID: 33637513; PMCID: PMC7919571. - DOI - PMC - PubMed